Martin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, Elena Hartmann, Itziar Salaverria, Grit Hutter, Patricia Perez-Galan, Gael Roue, Christiane Pott, Steven Le Gouill, Sergio Cortelazzo, Simon Rule, Georg Hess, Francesco Zaja, Umberto Vitolo, Michal Szymczyk, Jan Walewski, Vincent Ribrag, Michael Unterhalt, Olivier Hermine, Eva Hoster
Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in virtually all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of up to 15% long-term survivors has been identified with a rather indolent clinical course. Advanced stage disease is usually apparent already at first clinical manifestation; in general, conventional chemotherapy is only palliative and median duration of remissions is only 1-2 years...
December 2011: Leukemia & Lymphoma